The number of patients with hyperlipidemia is increasing in China with the life style change resulting from economic development and the rise of residents’ income. It is estimated that there are over 100 million patients with hyperlipidemia and 160 million patients with dyslipidemia in China. And the figures are increasing every year.
Atorvastatin is a common drug that lowers blood cholesterol levels. It was developed by Pfizer in the trade name of Lipitor. It has been proved that Atorvastatin is safe and can decrease major cardiovascular events for patients with coronary heart disease, ischemic stroke, diabetes and high-risk patients with cardiovascular diseases such as hypertension. By the end of 2017, the global sales of Lipitor had exceeded USD 150 billion, creating a miracle in global drug sales.
According to CRI, Atorvastatin has been growing rapidly since it entered China, with its sales revenue increasing from less than CNY 200 million in 2005 to more than CNY 2.21 billion in 2017. There is a high demand for Atorvastatin in China. In addition to Pfizer’s brand-name drug Lipitor, generic drugs of Beijing Jialin Pharmaceutical Co., Ltd., China Meheco Topfond Pharma Co., Ltd., Zhejiang Neo-Dankong Pharmaceutical Co., Ltd., Guangdong Baike Pharmaceutical Co., Ltd., etc. are also sold on the market. Pfizer captured the largest market share by sales value. Its market share exceeded 70% with a sales value over CNY 1.6 billion in 2017.
It is estimated that the number of patients with hyperlipidemia will continue to grow in China in the next few years, which will lead to a rising demand for Atorvastatin.
– Development environment of Atorvastatin in China
– Sales of Atorvastatin in China
– Prices of Atorvastatin in China
– Major Atorvastatin manufacturers in China
– Market share of Atorvastatin by dosage form in China
– Prospect of Chinese Atorvastatin Market, 2018-2022